
Bartomeu Piza Vallespir
Advertisement
Articles by Bartomeu Piza Vallespir


86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study
ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Erika P. Hamilton, MD,Marina Sharifi,Kristine Rinn,Wassim McHayleh,Rinat Yerushalmi,Neelima Vidula, MD,Joyce O’Shaughnessy, MD,Guiseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Bartomeu Piza Vallespir,Kathy Puyana Theall,Alessandro Paoli,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc

87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Erika P. Hamilton, MD,Eva Ciruelos,Ji-Yeon Kim,Elena López-Miranda,Elia Seguí,Neelima Vidula, MD,Joyce O’Shaughnessy, MD,Guiseppe Curigliano,Javier Cortés, MD,Alessandro Di Sanzo,Paula Muñoz Romero,Bartomeu Piza Vallespir,Manuel Dominguez,Kathy Puyana Theall,Alessandro Paoli,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc


Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology
2
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
3
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
4
Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC
5
